R
Roberto Hegg
Researcher at University of São Paulo
Publications - 89
Citations - 7661
Roberto Hegg is an academic researcher from University of São Paulo. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 24, co-authored 80 publications receiving 5264 citations.
Papers
More filters
Journal ArticleDOI
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga,Javier Cortes,Sung-Bae Kim,Seock-Ah Im,Roberto Hegg,Young-Hyuck Im,L Roman,Jose Luiz Pedrini,Tadeusz Pienkowski,Adam Knott,Emma Clark,Mark C. Benyunes,Graham Ross,Sandra M. Swain +13 more
TL;DR: The combination of pertuzumab plus trastuzumAB plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.
Journal ArticleDOI
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine,Jonathan A. Ledermann,Frédéric Selle,Val Gebski,Richard T Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Andres Poveda,Sandro Pignata,Michael Friedlander,Nicoletta Colombo,Philipp Harter,Keiichi Fujiwara,Isabelle Ray-Coquard,Susana Banerjee,Joyce F. Liu,Elizabeth S. Lowe,Ralph Bloomfield,Patricia Pautier,Tomasz Byrski,Giovanni Scambia,Maria Ornella Nicoletto,Fiona Nussey,Andrew R Clamp,Richard T. Penson,Amit M. Oza,Andrés Poveda Velasco,Manuel Rodrigues,Jean-Pierre Lotz,Diane Provencher,Aleix Prat Aparicio,Laura Vidal Boixader,Clare L. Scott,Kenji Tamura,Mayu Yunokawa,Alla Lisyanskaya,Jacques Medioni,Nicolas Pécuchet,Coraline Dubot,Thibault De La Motte Rouge,Marie-Christine Kaminsky,Béatrice Weber,Alain Lortholary,Christine Parkinson,Jonathan A. Ledermann,Sarah Williams,Jonathan Cosin,James Hoffman,Marie Plante,Allan Covens,Gabe S. Sonke,Florence Joly,Anne Floquet,H. Hirte,Amnon Amit,Tjoung-Won Park-Simon,Koji Matsumoto,Sergei Tjulandin,Jae Hoon Kim,Jae Hoon Kim,Laurence Gladieff,Roberto Sabbatini,David M. O'Malley,Patrick Timmins,Daniel Kredentser,Nuria Laínez Milagro,Maria Pilar Barretina Ginesta,Ariadna Tibau Martorell,Alfonso Gómez de Liaño Lista,Belén Ojeda González,Linda Mileshkin,Masaki Mandai,Ingrid A. Boere,Petronella B. Ottevanger,Joo-Hyun Nam,Elias Abdo Filho,Salima Hamizi,Francesco Cognetti,David Warshal,Elizabeth Dickson-Michelson,Scott Kamelle,Nathalie McKenzie,Gustavo C. Rodriguez,Deborah K. Armstrong,Eva Chalas,Paul Celano,Kian Behbakht,Susan E Davidson,Stephen Welch,Limor Helpman,Ami Fishman,Ilan Bruchim,Magdalena Sikorska,Anna Słowińska,Wojciech Rogowski,Mariusz Bidziński,Beata Śpiewankiewicz,Antonio Casado Herraez,César Mendiola Fernández,Martina Gropp-Meier,Toshiaki Saito,Kazuhiro Takehara,Takayuki Enomoto,Hidemichi Watari,Chel Hun Choi,Byoung-Gie Kim,Jae Weon Kim,Jae Weon Kim,Roberto Hegg,Ignace Vergote +110 more
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Journal ArticleDOI
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Andreas Schneeweiss,Stephen Chia,Tamas Hickish,Vernon Harvey,Alexandru Eniu,Roberto Hegg,C. Tausch,J.H. Seo,Y.-F. Tsai,Jayantha Ratnayake,V. McNally,Graham Ross,Javier Cortes +12 more
TL;DR: The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD, and the tolerability of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer was assessed.
Journal ArticleDOI
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Elizabeth A. Mittendorf,Hong Zhang,Carlos H. Barrios,Shigehira Saji,Kyung Hae Jung,Roberto Hegg,Andreas Koehler,Joohyuk Sohn,Hiroji Iwata,Melinda L. Telli,Cristiano Ferrario,Kevin Punie,Frédérique Penault-Llorca,Shilpen Patel,Anh Nguyen Duc,Mario Liste-Hermoso,Vidya Maiya,Luciana Molinero,Stephen Y. Chui,Nadia Harbeck +19 more
TL;DR: In patients with early-stage TNBC, neoadjuvant treatment with atezolizumab in combination with nab-paclitaxel and anthracycline-based chemotherapy significantly improved pathological complete response rates with an acceptable safety profile.
Journal ArticleDOI
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M Swain,Sandra M Swain,David Miles,Sung Bae Kim,Young-Hyuck Im,Seock-Ah Im,Vladimir Semiglazov,Eva Ciruelos,Andreas Schneeweiss,Sherene Loi,Estefania Monturus,Emma Clark,Adam Knott,Eleonora Restuccia,Mark C. Benyunes,Javier Cortes,Richy Agajanian,Rizvana Ahmad,Bahriye Aktas,Victor Hugo Alencar,Dino Amadori,Jurandyr Andrade,Fabio Franke,Catia Angiolini,Kenjiro Aogi,Jess Armor,Wichit Arpornwirat,Laura Assersohn,William Audeh,Walter E. Aulitzky,Sergio J Azevedo,Maria Alejandra Bartoli,Norberto Batista Lopez,María Bianconi,Laura Biganzoli,Ruemu E. Birhiray,Marianna Bitina,Ron Blachy,Kimberly L. Blackwell,Rita Blanchard,Paulette Blanchet,Ion Boiangiu,Barbara Bower,Christine Brezden-Masley,Adam Brufsky,Leanne Budde,Priscilla Caguioa,Lourdes Calvo,Mario Campone,Robert R. Carroll,Hugo Castro,Valorie Chan,Veena Charu,Saverio Cinieri,Michael R. Clemens,Emilio Alba Conejo,Eduardo Côrtes,Bruno Coudert,Eduardo Cronemberger,Daniel Cubero,Shaker R. Dakhil,Brooke R. Daniel,Neville Davidson,Maria De Fatima Gaui,Susana De La Cruz,Maria Del Pilar,Gilson Delgado,John Allan Ellerton,Cesar Estuardo,Louis Fehrenbacher,Jean-Marc Ferrero,Patrick J. Flynn,Malgorzata Foszczynska-Kloda,Sandra Franco,Hirofumi Fujii,Chris Gallagher,Teresa Gamucci,Nora Giacomi,Miguel Gil I Gil,Antonio Gonzalez Martin,Vera Gorbunova,Eugeny Gotovkin,Nathan B. Green,Elza Grincuka,Eva-Maria Grischke,Vincent Hansen,Jeffrey Hargis,Maik Hauschild,Roberto Hegg,Carolyn B. Hendricks,Robert Hermann,Paulo M. Hoff,Jun Horiguchi,Javier Hornedo Muguiro,Stefano Iacobelli,Kenichi Inoue,Gustavo Ismael,Yoshinori Itoh,Hiroji Iwata,Davi Jendiroba,Rosa Jochim,Alison Jones,Marianne Just,Andre Kallab,Mark Karwal,Masahiro Kashiwaba,Giraldo Kato,Peter A. Kaufman,Pirkko Kellokumpu-Lehtinen,Andreas Kirsch,Igor Kiselev,Paula Klein,Norio Kohno,Mikhail Kopp,Liljana Kostovska-Maneva,Mauricio Kotliar,Iveta Kudaba,Sherko Kümmel,Katsumasa Kuroi,Juan Lacava,Luciano Latini,Soo-Chin Lee,Mikhail Lichinitser,Christopher Lobo,Christoph Maintz,Jedzada Maneecahvakajorn,Alexander Marmé,Gloria Martinez,Norikazu Masuda,Mario Matwiejuk,Vladimir Merculov,Richard A. Michaelson,Luis Miguel,Hernandez Monroy,Filippo Montemurro,Serafin Morales,Rodrigo Moura,Volkmar Mueller,Clive Mulatero,Kazuhiko Nakagami,Takahiro Nakayama,Jeff Neidhart,An Nguyen,Reiki Nishimura,Haruki Ogata,S O'Reilly,Timothy J. O'Rourke,Douglas Otero Reye,Xuenong Ouyang,Ravi Patel,Taral Patel,Jose Luiz Pedrini,Rodrigo Pereira,Alejandra Perez,Carol Peterson,Tadeusz Pienkowski,Helio Pinczowski,Jonathan Polikoff,Wojciech Polkowski,Paola Edith Price,Sue Prill,Frank Priou,Gunta Purkalne,Seppo Pyrhoenen,Robert Quackenbush,Yoshiaki Rai,Nuria Ribelles,Jungsil Ro,Anne Robinson,Robert Robles,Gladys Rodriguez,L Roman,Shigehira Saji,Pedro Sánchez-Rovira,Nobuaki Sato,Marcus Schmidt,Claudia Schumacher,Frank Senecal,Priyanka Sharma,Zhenzhou Shen,Vadim Shirinkin,Edda Simoncini,Thitiya Sirisinha,Raymond Smith,Joohyuk Sohn,Zeljko Soldic,Tania Soria,Darcy Spicer,Vichien Srimuninnimit,Virote Sriuranpong,Elżbieta Starosławska,Petar Stefanovski,Patrapim Sunpaweravong,Julie Taguchi,Koji Takeda,Gabriel Tellez-Trevilla,Randall Thomas,Christoph Thomssen,Zetina Toache,Yutaka Tokuda,Piotr Tomczak,Celia Tosello,Koichiro Tsugawa,Dennis Tudtud,Takayuki Ueno,Brigitte Van Eyll,Mirta Varela,Nikola Vasev,Damir Vrbanec,Xiaojia Wang,Liwei Wang,Junichiro Watanabe,David Waterhouse,Birgitta Wesenberg,Duncan Wheatley,Zee Wan Wong,Sanjay Yadav,Denise A. Yardley,Tsz-Kok Yau,Winnie Yeo,Cheng Ying,Do Youn Oh +221 more
TL;DR: The end-of-study analysis of CLEOPATRA found progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group, and the overall survival rates were also significantly improved.